Analysts expect Liquidia Co. (NASDAQ:LQDA – Get Rating) to report revenue of $3.51 million for the current fiscal quarter, Zacks reports. Three analysts have made estimates of Liquidia’s earnings, with estimates ranging from $3.06 million to $3.80 million. Liquidia reported sales of $3.38 million in the same quarter last year, suggesting a positive year-over-year growth rate of 3.8%. The company is due to release its next results on Monday, January 1.

On average, analysts expect Liquidia to post annual revenue of $17.58 million for the current fiscal year, with estimates ranging from $14.09 million to $22.80 million. dollars. For the next fiscal year, analysts expect the company to report sales of $53.18 million, with estimates ranging from $24.34 million to $90.30 million. Zacks Investment Research’s sell calculations are an average based on a survey of sell-side research analysts who cover Liquidia.

Liquidia (NASDAQ:LQDA – Get Rating) last released its results on Thursday, May 12. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analyst consensus estimates of ($0.20) by ($0.10). During the same period of the previous year, the company posted ($0.21) EPS.

LQDA has been the subject of several research analyst reports. Bank of America began covering Liquidia shares in a research report on Thursday, May 26. They issued a “buy” rating and a price target of $12.00 on the stock. BTIG Research began covering Liquidia shares in a report on Tuesday, May 31. They set a “buy” rating and a price target of $14.00 for the company. Finally, Zacks Investment Research downgraded Liquidia shares from a “hold” rating to a “sell” rating in a Wednesday, April 6 research note. One financial analyst gave the stock a sell rating, one gave the company a hold rating and four gave the company a buy rating. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $11.17.

NASDAQ: LQDA opened at $4.32 on Monday. Liquidia has a 1-year low of $2.25 and a 1-year high of $7.78. The company’s fifty-day simple moving average is $5.57 and its 200-day simple moving average is $5.58. The company has a market capitalization of $277.97 million, a PE ratio of -5.40 and a beta of 0.35.

In related news, Director Caligan Partners Lp purchased 1,764,705 shares of the company in a transaction on Monday April 18. The shares were purchased at an average price of $5.10 per share, for a total transaction of $8,999,995.50. Following completion of the transaction, the administrator now directly owns 10,093,123 shares of the company, valued at approximately $51,474,927.30. The acquisition was disclosed in a filing with the SEC, accessible via the SEC’s website. Additionally, Chief Financial Officer Michael Kaseta purchased 18,700 shares of the company in a transaction dated Tuesday, May 31. The shares were purchased at an average cost of $4.01 per share, for a total transaction of $74,987.00. Following the completion of the purchase, the CFO now directly owns 27,950 shares of the company, valued at approximately $112,079.50. Disclosure of this purchase can be found here. Insiders have acquired 2,065,133 shares of the company worth $10,395,378 in the past 90 days. Insiders of the company hold 29.50% of the shares of the company.

A number of hedge funds have recently increased or reduced their holdings in the stock. UBS Group AG increased its position in Liquidia shares by 205.4% during the third quarter. UBS Group AG now owns 10,151 shares of the company worth $28,000 after purchasing an additional 6,827 shares during the period. Marshall Wace LLP purchased a new stake in Liquidia during the first quarter worth approximately $32,000. Qube Research & Technologies Ltd purchased a new equity stake in Liquidia during the fourth quarter worth $55,000. Dorsey Wright & Associates bought a new position in Liquidia in Q1 worth around $57,000. Finally, BNP Paribas Arbitrage SA increased its position in Liquidia shares by 4,365.4% during the 4th quarter. BNP Paribas Arbitrage SA now owns 12,771 shares in the company valued at $62,000 after purchasing an additional 12,485 shares in the last quarter. Institutional investors and hedge funds hold 27.68% of the company’s shares.

Liquidia company profile (Get a rating)

Liquidia Corporation, a biopharmaceutical company, develops, manufactures and markets various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension.

Read more

Get a Free Copy of Zacks Research Report on Liquidia (LQDA)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Liquidia right now?

Before you consider Liquidia, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Liquidia wasn’t on the list.

Although Liquidia currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here